**Chapter 4**

*The Universe of Escherichia coli*

One. 2010;**5**:e10386

2012;**54**:255-262

[106] Patel A, Mamtani M, Dibley MJ, et al. Therapeutic value of zinc supplementation in acute and persistent diarrhea: A systematic review. PLoS

of the recombinant enteropathogenic *Escherichia coli* vaccine candidates BfpA and EspB. Protein Expression and Purification. 2002;**25**:16-22

[113] Sanches MI, Keller R, Hartland EL, et al. Human colostrum and serum contain antibodies reactive to the intimin-binding region of the enteropathogenic *Escherichia coli* translocated intimin receptor. Journal of Pediatric Gastroenterology and

[114] Stakenborg T, Vandekerchove D, Mariẽn J, et al. Protection of rabbits against enteropathogenic *Escherichia coli* (EPEC) using an intimin null mutant. BMC Veterinary Research. 2006;**2**:22

[115] Tacket CO, Sztein MB, Losonsky G, et al. Role of EspB in experimental human enteropathogenic *Escherichia coli* infection. Infection and Immunity.

[116] Carbonare SB, Silva ML, Palmeira P, Carneiro-Sampaio MM. Human colostrum IgA antibodies reacting to enteropathogenic *Escherichia coli* antigens and their persistence in the faeces of a breastfed infant. Journal of Diarrhoeal Diseases Research. 1997;**15**:53-58

[117] Donnenberg MS, Tacket CO, Losonsky G, et al. Effect of prior experimental human enteropathogenic *Escherichia coli* infection on illness following homologous and heterologous re-challenge. Infection and Immunity.

[118] Loureiro I, Frankel G, Adu-Bobie J, et al. Human colostrum contains IgA antibodies reactive to enteropathogenic *Escherichia coli* virulence-associated proteins: Intimin, BfpA, EspA, and EspB. Journal of Pediatric Gastroenterology and Nutrition.

Nutrition. 2000;**30**:73-77

2000;**68**:3689-3695

1998;**66**:52-58

1998;**27**:166-171

[107] Liu J, Wang WD, Liu YJ, et al. Mice vaccinated with enteropathogenic *Escherichia coli* ghosts show significant protection against lethal challenges. Letters in Applied Microbiology.

[108] Costa-Carvalho BT, Bertipaglia

A, Solé D, et al. Detection of immunoglobulin (IgG and IgA) anti-outer membrane proteins of enteropathogenic *Escherichia coli* (EPEC) in saliva, colostrum, breast milk, serum, cord blood and amniotic fluid. Study of inhibition of localized adherence of EPEC to HeLa cells. Acta

Paediatrica. 1994;**83**:870-873

1991;**163**:1247-1255

2003;**21**:1725-1731

2000;**38**:2696-2700

[111] Parissi-Crivelli A, Parissi-Crivelli JM, Girón JA. Recognition of enteropathogenic *Escherichia coli* virulence determinants by human colostrum and serum antibodies. Journal of Clinical Microbiology.

[112] Quintana Flores VM, Fernandes RCCS, Sousa de Macedo Z, Medina-Acosta E. Expression and purification

[109] Cravioto A, Tello A, Villafan H, et al. Inhibition of localized adhesion of enteropathogenic *Escherichia coli* to HEp-2 cells by immunoglobulin and oligosaccharide fractions of humancolostrum and breast milk. The Journal of Infectious Diseases.

[110] Fernandes RCSC, Quintana Flores VM, Sousa de Macedo Z, Medina-Acosta E. Coproantibodies to the

enteropathogenic *Escherichia coli* vaccine candidates BfpA and EspB in breast fed and artificially fed children. Vaccine.

**68**
